Table of Contents

company-logo

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Dividend Announcement

• Sarepta Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Sarepta Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Sarepta Therapeutics Dividend History

Sarepta Therapeutics Dividend Yield

Sarepta Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Sarepta Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Sarepta Therapeutics Financial Ratios

P/E ratio91.51
PEG ratio26.38
P/B ratio9.13
ROE11.83%
Payout ratio0.00%
Current ratio3.84
Quick ratio3.03
Cash Ratio0.28

Sarepta Therapeutics Dividend FAQ

Does Sarepta Therapeutics stock pay dividends?
Sarepta Therapeutics does not currently pay dividends to its shareholders.
Has Sarepta Therapeutics ever paid a dividend?
No, Sarepta Therapeutics has no a history of paying dividends to its shareholders. Sarepta Therapeutics is not known for its dividend payments.
Why doesn't Sarepta Therapeutics pay dividends?
There are several potential reasons why Sarepta Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Sarepta Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Sarepta Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Sarepta Therapeutics a dividend aristocrat?
Sarepta Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Sarepta Therapeutics a dividend king?
Sarepta Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Sarepta Therapeutics a dividend stock?
No, Sarepta Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Sarepta Therapeutics stocks?
To buy Sarepta Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Sarepta Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.